Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).

ABSTRACT:

Background

Hepatitis C virus (HCV)/HIV coinfection treatment is suboptimal with low sustained viral response rates to standard therapies. A multicenter randomized clinical trial designed to assess the efficacy/safety of pegylated interferon maintenance therapy was performed by the National Institutes of Health-funded AIDS Clinical Trials Group network.

Methods

HCV treatment-naive and nonresponding interferon-experienced subjects with confirmed HCV and HIV, CD4 >200 cells per cubic millimeter, and at least stage 1 fibrosis were enrolled and treated for 12 weeks with pegylated interferon alfa 2a 180 mcg per week (PEG) + weight-based ribavirin to determine response status. Nonresponder subjects (failure to clear HCV RNA or achieve 2-log drop) underwent liver biopsy and were ran

SUBMITTER: Sherman KE 

PROVIDER: S-EPMC3017670 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature